Year: 2024
Type: article
Abstract: The recent lipid management guidelines emphasize using low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (non-HDL-C), and apo B levels as treatment targets.Out of these, LDL-C is the primary target of lipid management, non-HDL-C is the co-primary and ApoB is the secondary target.One-time estimation of lipoprotein(a) is sufficient presently to assess risk in view of the lack of specific drugs targeting it.Triglyceride levels ≥150 mg/dL in fasting and ≥175 mg/dL in non-fasting samples are considered risk modifiers for atherosclerotic cardiovascular disease.Lipid profile estimation in a non-fasting sample is considered good enough to manage a dyslipidemia patient.The inclusion of risk group-specific target range of lipid profile in biochemistry report format shall be more informative and helpful in ensuring better patient compliance.
Author: Shalini Gupta
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4405674361